“This usual chain of decisions … has been disrupted. And without clarity and coordination, millions may not be able to have ...

James Brumley has positions in Coca-Cola. The Motley Fool has positions in and recommends Amazon, Equifax, MercadoLibre, ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate PFE stock a Sell.

Financisation is killing the economy. When companies such as Apple and Pfizer spend more on share buy-backs than on R&D, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a ...

AI is making an impact in the early stages of drug discovery. It can scan huge chemical and biological datasets, predict how ...

China's pharmaceutical industry currently ranks as the second largest in the world, with the number of innovative drugs in ...

Pfizer stock currently trades at very low volatility. That could mean it’s ripe for a breakout trade, like a long strangle.

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...